Company Description
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis.
The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder.
It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited.
DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Sep 28, 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | James Brown |
Contact Details
Address: 10240 Bubb Road Cupertino, California 95014-4166 United States | |
| Phone | 408 777 1417 |
| Website | durect.com |
Stock Details
| Ticker Symbol | DRRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082038 |
| CUSIP Number | 266605104 |
| ISIN Number | US2666055007 |
| Employer ID | 94-3297098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James E. Brown D.V.M. | Co-Founder, Chief Executive Officer, President and Director |
| Timothy M. Papp M.B.A. | Chief Financial Officer and Secretary |
| Dr. Norman L. Sussman M.D. | Chief Medical Officer |
| Judy R. Joice | Senior Vice President of Operations and Corporate Quality Assurance |
| Steve Helmer J.D. | Vice President and Chief Patent Counsel |
| Dr. WeiQi Lin M.D., Ph.D. | Executive Vice President of Research and Development and Principal Scientist |
| Jian Li M.B.A. | SVice President of Finance and Corporate Controller |
| Dr. Su Il Yum Ph.D. | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 12, 2025 | SC 14D9 | Filing |
| Aug 12, 2025 | SC TO-T | Filing |
| Aug 8, 2025 | SC14D9C | Filing |
| Aug 8, 2025 | 8-K | Current Report |
| Jul 31, 2025 | SC TO-C | Filing |
| Jul 30, 2025 | SC TO-C | Filing |
| Jul 29, 2025 | SC14D9C | Filing |
| Jul 29, 2025 | SC14D9C | Filing |